NUCOLL43 Cell Line
Invented by Prof Nicola Curtin from University of Newcastle upon Tyne
- References (2)
- Inventor Info
|Parental Line||Clear cell adenocarcinoma of gynecological origin|
|Synonyms||O-CCC, ovarian clear cell carcinoma, HGSC, high grade ovarian cancer, TP53, CA125, LOH, loss of heterozygosity|
|Disease Keywords||Ovarian clear cell carcinoma|
Ovarian cancer is a significant cause of death in women worldwide with the majority of ovarian cancers forming in women under the age of 65. Due to late stage diagnosis and a lack of reliable screening tests, survival rates after 5 years are below 50% in developing counties.
Ovarian cancer can spread to tissues in close proximity to the ovaries, including the lining of the abdomen, lungs, lymph nodes and liver. Ovarian cancer has a number of histological subtypes and ovarian clear cell carcinomas generally respond poorly to chemotherapy
|Research Area||Cancer, Cell Cycle, Gene Expression, Genetic Studies Tools, Reproductive Biology|
|Growth/Phenotype Keywords||Doubling time approximately 45 hours|
|Recommended Growing Conditions||RPMI-1640 media supplemented with 20% FBS and cultured at 37C in 5% CO2.|
NUCOLL43 was established from ascitic fluid from a female 57 year old white British patient without artifical immortalisation.
Cells display a complete loss of TP53 expression and function despite having no loss of chromosome 17p and show highly similar pan-genomic similarity to the original patient tumor. Like the original tumor, the cells also expressed epithelial and mesenchymal characteristics.
NUCOLL43 cells poses a very high degree of loss of heterozygosity which affected 85% of the genome.
NUCOLL43 cells are resistant to cisplatin and rucaparib, but sensitive to paclitaxel, camptothecin and NVP-BEZ 235.
There are 2 reference entries for this reagent.View All References
Add an inventor